IMMUNITYBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 175.53K shares.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 233.75K shares, a 112.46% increase year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 110.02K shares, a 64.39% decline from fiscal 2024.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 308.96K shares, a 67.58% increase from fiscal 2023.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 184.36K shares, a 1148.47% increase from fiscal 2022.
- IMMUNITYBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 14.77K shares, a 99.19% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 175.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 409.28K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 233.75K shares 10-Q · filed 2026-05-07 | 233.75K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 110.02K shares 10-K · filed 2026-02-23 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 110.02K shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 272.78K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 110.02K shares 10-Q · filed 2025-05-12 | 418.98K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 308.96K shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 162.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 310.08K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 146.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 222.94K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2024-05-09 | 103.33K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 1.13K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 184.36K shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 75.62K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 183.24K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 26.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 107.62K shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 81.04K shares 10-Q · filed 2023-05-11 | 81.04K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 14.77K shares 10-K · filed 2023-03-01 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 84.11K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | |
| 2022-03-31 | 14.77K shares 10-Q · filed 2022-05-10 | |
| 2021-12-31 | 69.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 1.82M shares 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |